BioStem Technologies ((BSEM)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
BioStem Technologies is conducting a clinical study titled ‘A Prospective, Multicenter, Randomized, Controlled Trial of Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC.’ The study aims to evaluate the effectiveness of the BR-AC treatment, a human placental allograft, in promoting the healing of non-healing venous leg ulcers compared to standard care alone. This research is significant as it could offer a new therapeutic option for patients with chronic wounds.
The intervention being tested is BR-AC, a placental membrane product designed to enhance wound healing. It is applied directly to the wound surface, aiming to achieve complete healing within 12 weeks.
The study employs a randomized, controlled design with a parallel intervention model. It features single masking, where an independent reviewer assesses wound closure to minimize bias. The primary purpose is treatment-focused.
The study began on February 14, 2025, with primary completion expected within 12 weeks of treatment initiation. The latest update was submitted on July 24, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This update could positively impact BioStem Technologies’ stock performance by enhancing investor confidence in the company’s innovative treatments. The study’s success might also influence the competitive landscape in the wound care industry.
The study is ongoing, with further details available on the ClinicalTrials portal.